| Davidson's principles and practice of medicine e-book BR Walker, NR Colledge Elsevier Health Sciences, 2013 | 883* | 2013 |
| T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 … PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ... Journal of Clinical Oncology 37 (4), 318-327, 2019 | 765 | 2019 |
| Davidson's principles and practice of medicine NR Colledge, BR Walker, S Ralston, LSP Davidson (No Title), 2014 | 496 | 2014 |
| Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ... Journal of Clinical Oncology 35 (34), 3851-3858, 2017 | 458 | 2017 |
| Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers R Plummer, G Attard, S Pacey, L Li, A Razak, R Perrett, M Barrett, ... Clinical cancer research 13 (20), 6187-6194, 2007 | 295 | 2007 |
| Nasopharyngeal carcinoma: the next challenges ARA Razak, LL Siu, FF Liu, E Ito, B O’Sullivan, K Chan European journal of cancer 46 (11), 1967-1978, 2010 | 264 | 2010 |
| Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma BH O’Neil, JM Wallmark, D Lorente, E Elez, J Raimbourg, C Gomez-Roca, ... PloS one 12 (12), e0189848, 2017 | 261 | 2017 |
| Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors S Leijen, RMJM van Geel, AC Pavlick, R Tibes, L Rosen, ARA Razak, ... Journal of Clinical Oncology 34 (36), 4371-4380, 2016 | 252 | 2016 |
| Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ... Genome medicine 8, 1-12, 2016 | 247 | 2016 |
| Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants BD Smith, MD Kaufman, WP Lu, A Gupta, CB Leary, SC Wise, TJ Rutkoski, ... Cancer cell 35 (5), 738-751. e9, 2019 | 244 | 2019 |
| Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial WD Tap, AJ Wagner, P Schöffski, J Martin-Broto, A Krarup-Hansen, ... Jama 323 (13), 1266-1276, 2020 | 235 | 2020 |
| First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors AR Abdul Razak, M Mau-Soerensen, NY Gabrail, JF Gerecitano, ... Journal of Clinical Oncology 34 (34), 4142-4150, 2016 | 226 | 2016 |
| A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors TW Chen, AR Razak, PL Bedard, LL Siu, AR Hansen Annals of Oncology 26 (9), 1824-1829, 2015 | 215 | 2015 |
| Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status SH Huang, JN Waldron, M Milosevic, X Shen, J Ringash, J Su, L Tong, ... Cancer 121 (4), 545-555, 2015 | 177 | 2015 |
| Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) H Hammers, ER Plimack, JR Infante, M Ernstoff, BI Rini, DF McDermott, ... Annals of Oncology 25, iv361, 2014 | 173 | 2014 |
| Validation of CyTOF against flow cytometry for immunological studies and monitoring of human cancer clinical trials R Gadalla, B Noamani, BL MacLeod, RJ Dickson, M Guo, W Xu, ... Frontiers in oncology 9, 415, 2019 | 169 | 2019 |
| Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma MM Gounder, A Zer, WD Tap, S Salah, MA Dickson, AA Gupta, ... Journal of Clinical Oncology 34 (26), 3166-3174, 2016 | 160 | 2016 |
| Hyperprogressive disease in early‐phase immunotherapy trials: clinical predictors and association with immune‐related toxicities Y Kanjanapan, D Day, L Wang, H Al‐Sawaihey, E Abbas, A Namini, ... Cancer 125 (8), 1341-1349, 2019 | 144 | 2019 |
| Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone F Traub, J Singh, BC Dickson, S Leung, R Mohankumar, ME Blackstein, ... European journal of cancer 59, 1-12, 2016 | 142 | 2016 |
| A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors SF Jones, LL Siu, JC Bendell, JM Cleary, ARA Razak, JR Infante, ... Investigational new drugs 33, 1100-1107, 2015 | 136 | 2015 |
Lillian SiuPrincess Margaret Cancer Centre在 uhn.ca 的电子邮件经过验证
